EyePoint (EYPT) Following LUGANO Data Is The Undervalued Narrative Still Intact

Simply Wall St.

Aug 18

EyePoint (EYPT) is back in focus after topline data from its pivotal LUGANO Phase 3 trial of DURAVYU in wet age related macular degeneration, raising fresh questions and interest around the stock. See...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2660693374"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2660693374\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2660693374?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-08-18 17:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2660693374","market":"us","top_or_hot":-1,"title":"EyePoint (EYPT) Following LUGANO Data Is The Undervalued Narrative Still Intact","media":"Simply Wall St.","content":"<div>\n<p>EyePoint (EYPT) is back in focus after topline data from its pivotal LUGANO Phase 3 trial of DURAVYU in wet age related macular degeneration, raising fresh questions and interest around the stock. See...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/news/eyepoint-eypt-following-lugano-data-is-the-undervalued-narra\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EyePoint (EYPT) Following LUGANO Data Is The Undervalued Narrative Still Intact</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEyePoint (EYPT) Following LUGANO Data Is The Undervalued Narrative Still Intact\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-18 17:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/news/eyepoint-eypt-following-lugano-data-is-the-undervalued-narra><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>EyePoint (EYPT) is back in focus after topline data from its pivotal LUGANO Phase 3 trial of DURAVYU in wet age related macular degeneration, raising fresh questions and interest around the stock. See...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/news/eyepoint-eypt-following-lugano-data-is-the-undervalued-narra\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/news/eyepoint-eypt-following-lugano-data-is-the-undervalued-narra","article_id":"2660693374","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/news/eyepoint-eypt-following-lugano-data-is-the-undervalued-narra","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2660693374","pubTimestamp":1787045177,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"EyePoint (EYPT) is back in focus after topline data from its pivotal LUGANO Phase 3 trial of DURAVYU in wet age related macular degeneration, raising fresh questions and interest around the stock.\nSee our latest analysis for EyePoint.\nThe LUGANO readout has sharply reset expectations around EyePoint, with the share price down about 73% year to date and the 1 year total shareholder return declining about 57%. This points to fading momentum as investors reassess both execution risk and future...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4588":"碎股","BK4585":"ETF&股票定投概念","EYPT":"EyePoint","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC"},"translate_title":"卢加诺数据之后的 EyePoint (EYPT) 是被低估的叙述仍然完好无损","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EYPT":1.5},"content_text":"EyePoint (EYPT) is back in focus after topline data from its pivotal LUGANO Phase 3 trial of DURAVYU in wet age related macular degeneration, raising fresh questions and interest around the stock. See our latest analysis for EyePoint. The LUGANO readout has sharply reset expectations around EyePoint, with the share price down about 73% year to date and the 1 year total shareholder return declining about 57%. This points to fading momentum as investors reassess both execution risk and future growth potential. If this kind of clinical trial swing has you reassessing your watchlist, it can be useful to compare other ophthalmology and biotech names using a healthcare focused screen, including 40 healthcare AI stocks. EyePoint now trades far below the average analyst price target, yet the LUGANO miss and widening losses show why the market has pulled back hard. Is that markdown an overreaction to a messy dataset, or does it reflect justified caution? AdvertisementMost Popular Narrative: 88% Undervalued At a last close of $4.87 versus a narrative fair value of about $40.54, EyePoint is framed as heavily discounted, with that gap resting on some bold assumptions.  Analysts are assuming EyePoint's revenue will grow by 259.6% annually over the next 3 years. Analysts are not forecasting that EyePoint will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate EyePoint's profit margin will increase from 3567.1% to the average AU Pharmaceuticals industry of 19.7% in 3 years.  Read the complete narrative. Want to see what has to go right for that valuation gap to close? The narrative leans on rapid revenue expansion, margin rebuilding, and a rich future earnings multiple. Curious which specific milestones and forecast ranges sit underneath those assumptions? Result: Fair Value of $40.54 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the EyePoint story still hinges heavily on DURAVYU approvals and commercialization. Ongoing losses and minimal current revenue leave little buffer if timelines slip. Find out about the key risks to this EyePoint narrative. Next Steps With EyePoint's story pulling in different directions, it makes sense to move quickly and review the underlying data yourself. To see how the balance of concerns and potential upsides stacks up, start with the 1 key reward and 5 important warning signs. Looking for more investment ideas beyond EyePoint? If EyePoint has sharpened your focus on stock selection, do not stop here. Use the Simply Wall Street Screener to spot fresh ideas before others notice.  Target potential mispricings by scanning for companies that look attractively valued using the 53 high quality undervalued stocks. Prioritise resilience by zeroing in on businesses with strong finances through the solid balance sheet and fundamentals stocks screener (50 results). Hunt for early stage standouts that the market may be overlooking with the screener containing 19 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if EyePoint might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}